The global biosurgery market size was valued at USD 11.4 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2019 to 2026. Factors such as the availability of multifunctional products that accelerate healing and help reduce post-surgical recovery duration are expected to fuel the growth. Biosurgery products are used in surgical procedures for adhesion or wound sealing and healing damaged bones and tissues. The rise in surgical procedures is expected to positively influence product demand.
Biosurgery is also known as maggot therapy or larva therapy. These maggots or larvae are used to heal chronically infected wounds, which are resistant to antibiotics. Biosurgery with maggot debridement therapy has also proven effective for diabetic patients. High prevalence of diabetes and spinal injuries is anticipated to propel the demand for biosurgery in the forthcoming years. In addition, biosurgery is also beneficial in orthopedic, neurological, and gynecology surgeries, fueling product demand.
Rising demand for minimally invasive surgery coupled with a continual rise in the aging population with chronic conditions is expected to drive the biosurgery market. Products used for biosurgery reduce the risk associated with tissue contamination, which in turn is expected to drive their demand. Furthermore, effective measures for blood loss during surgeries are expected to propel the adoption of these procedures during the forecast period.
Factors such as advancements in surgeries and novel product launch to help surgeons perform surgeries efficiently are expected to further fuel the market. According to the National Health Statistics report, during 28.6 million ambulatory surgery visits to ambulatory surgical centers and hospitals in the U.S., approximately 48.3 million surgical and nonsurgical procedures were performed in 2010. Rising incidence of chronic disorders and acute diseases among the geriatric population coupled with increasing demand for improved surgical care for patients of all ages is further augmenting the growth. Moreover, innovations in marketing strategies of medical devices and growing medical tourism in developing countries are creating opportunities for manufacturers to expand their customer base in emerging economies.
The surgical sealants segment is expected to dominate the market for biosurgery over the forecast period due to the rising incidence of sports-related injuries and lower back pain. Moreover, a high prevalence of lifestyle diseases coupled with a rise in the number of surgeries performed annually is anticipated to propel the market growth in the forthcoming years.
The soft tissue attachment segment is expected to register the fastest CAGR over the forecast period, attributed to rising applications in various surgical procedures. Soft tissue healing is a significant measure in determining the outcome of various osseous surgery. Different methods such as pedicle grafting and free grafting both split thickness and full are used to execute primary soft tissue closure.
General surgery accounted for the largest market size of 3.8 billion in 2018 and is expected to register a CAGR of 8.6% over the forecast period. The growth is primarily attributed to the technological advancements and rising adoption of advanced surgeries in developing economies. The orthopedic surgery segment account for the second-largest market share in 2018, attributed to the prevalence of bone diseases, rising geriatric population, and cases of road accidents. Moreover, increasing the use of biosurgery products in orthopedic surgery, improving diagnostic methods, and the introduction of new products launch are the factors expected to propel the segment over the forecast period.
The cardiology surgery segment is expected to register the fastest CAGR during the forecast period. According to the American Heart Association Research, cardiovascular disease accounts for more than 840,678 deaths in the U.S. in 2016. Increasing prevalence of heart disease and diabetes, growing healthcare investment, and technological advancements are some of the factors driving the growth of the segment.
North America is expected to continue holding the leading biosurgery market share over the forecast period, owing to its well-established healthcare sector. The increasing prevalence of obesity and cardiovascular diseases is also expected to drive regional growth. The rising adoption of advanced surgical tools and devices is expected to create growth opportunities for the regional market in the near future.
Europe is expected to capture the second-largest market share over the forecast period, due to an increase in the geriatric population, which is prone to various illnesses. Moreover, improvements in the healthcare sector and the implementation of advanced medical products are augmenting the regional demand for biosurgery.
Asia Pacific (APAC) is projected to be a lucrative region for biosurgery with the fastest CAGR over the forecast period. Improvements in healthcare facilities and reimbursement policies in developing economies are expected to aid regional growth. Japan spearheaded the APAC region in 2018 owing to its large geriatric population and rapid economic growth. Furthermore, an increase in awareness regarding advanced surgical procedures is expected to boost demand during the forecast period.
Most prominent players focus on new product launches, acquisitions, advancement in existing products and technologies, and other such strategies to expand their product portfolio and strengthen their market presence. For instance, in September 2018, Baxter International Inc., a global medical product company announced an agreement to acquire two sealant and hemostat products from Mallinckrodt plc. This agreement will enhance the market share and product portfolio of the former. Some of the prominent players in the biosurgery market include:
Johnson & Johnson (Ethicon)
Medtronic Plc
Strykers
Baxter International Inc.
C.R. Bard
Sanofi
Pfizer
B. Braun Melsungen AG
Integra Lifesciences Corporation
Report Attribute |
Details |
Market size value in 2020 |
USD 13.6 billion |
Revenue forecast in 2026 |
USD 20.1 billion |
Growth Rate |
CAGR of 7.1% from 2019 to 2026 |
Base year for estimation |
2018 |
Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Quantitative units |
Revenue in USD million and CAGR from 2019 to 2026 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Japan; China; India; Thailand; South Korea; Brazil; Mexico ; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Johnson & Johnson (Ethicon); Medtronic Plc; Strykers; Baxter International Inc.; C.R. Bard; Sanofi; Pfizer; B. Braun Melsungen AG; Integra Lifesciences Corporation |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels as well as provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global biosurgery market report on the basis of product, application, and region:
Product Outlook (Revenue, USD Million, 2015 - 2026)
Surgical Sealants
Hemostatic Agents
Adhesion Barriers
Soft Tissue Attachments
Bone Graft Attachments
Others
Application Outlook (Revenue, USD Million, 2015 - 2026)
General Surgery
Orthopedic Surgery
Cardiovascular surgery
Neurological Surgery
Others
Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
The U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
Japan
China
India
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global biosurgery market size was estimated at USD 12.5 billion in 2019 and is expected to reach USD 13.6 billion in 2020.
b. The global biosurgery market is expected to grow at a compound annual growth rate of 7.1% from 2019 to 2026 to reach USD 20.1 billion by 2026.
b. North America dominated the biosurgery market with a share of 47.0% in 2019. This is attributable to the well-established healthcare sector, increasing prevalence of obesity, and cardiovascular diseases.
b. Some key players operating in the biosurgery market include Johnson & Johnson (Ethicon); Medtronic Plc; Strykers; Baxter International Inc.; C.R. Bard; Sanofi; Pfizer; B. Braun Melsungen AG; and Integra Lifesciences Corporation.
b. Key factors that are driving the market growth include increasing number of surgical procedures, increasing incidence of diabetes and chronic diseases and rising geriatric population across the world.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.